Morningstar Q2 Earnings Show Core Strength, But Index Monetization Story Still Unproven

What happened

Morningstar reported second-quarter 2026 results featuring broad-based growth in revenue, operating income, and margins, with CEO Kunal Kapoor highlighting meaningful increases in operating and free cash flow and an ambitious strategy centered on agentic workflows. The release confirmed the company is delivering on its profitable growth narrative, yet it remained silent on the specific metrics that matter most for the investment thesis: post-CRSP index revenue trajectory, Vanguard contract details, and integration milestones. Without this granularity, the market lacks evidence that the acquired CRSP scale is converting into above-trend licensing revenue or that benchmark-client concentration risk is being mitigated. The sturdy quarter reinforces Morningstar’s underlying earnings power, currently supporting a base-case valuation near $185, but the index monetization catalyst that could drive a re-rating toward $215 remains unvalidated. Consequently, the stock is likely to stay in a show-me phase until upcoming disclosures provide hard proof of index revenue acceleration and margin durability.

Implication

Morningstar’s solid Q2 results with expanding margins and cash flows confirm the strength of its core platform and data businesses, supporting the base-case valuation near $185. However, the earnings release lacked details on the CRSP integration or progress in converting the acquired index scale into above-trend revenue, which is the linchpin for the bull case. Without visible acceleration in Indexes revenue or new benchmark mandate wins, the stock is likely to remain range-bound near its current valuation, as the market awaits concrete proof of monetization. Investors should monitor the next quarters for index revenue trajectory and any Vanguard-related disclosures, as these will determine whether the stock can re-rate toward the bull scenario of $215 or slip back toward the bear case of $135. The balance of evidence suggests holding the position while watching for early indicators of thesis progress.

Thesis delta

The thesis remains unchanged: Q2 results reinforce the existing base case but do not provide the index-specific acceleration needed to upgrade conviction. The lack of update on CRSP integration and index revenue means the central risk—concentrated benchmark client economics and unproven monetization—persists. We maintain our POTENTIAL BUY rating and base-case target, with the key trigger being upcoming quarters’ index performance.